Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22508748 | 0.81 | ALDH1A1 (0.42) | TSHRNPC1ALDH1A1TAAR1L3MBTL1 | |
| SCHEMBL16106831 | 0.80 | TSHR (0.44) | TSHRNPC1ALDH1A1TAAR1POLB | |
| SCHEMBL19672964 | 0.79 | EGLN1 (0.38) | EGLN1ALDH1A1ZDHHC20SLC1A3SLC1A2 | |
| SCHEMBL16401454 | 0.78 | NPC1 (0.39) | TSHRNPC1ALDH1A1TAAR1POLB | |
| SCHEMBL15549900 | 0.77 | HTT (0.51) | TSHRALDH1A1TAAR1L3MBTL1ZDHHC20 | |
| SCHEMBL1264448 | 0.77 | — | — | |
| SCHEMBL10245233 | 0.77 | — | — | |
| SCHEMBL9353138 | 0.76 | EGLN1 (0.36) | EGLN1ALDH1A1LMNAMAPTPTGS2 | |
| SCHEMBL22508885 | 0.76 | TSHR (0.49) | TSHRL3MBTL1ZDHHC20CYP1A2CYP2D6 | |
| SCHEMBL15806526 | 0.75 | L3MBTL1 (0.51) | L3MBTL1ZDHHC20TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | disclosed |
| WO-2025111431-A1 | ANTI-CD7 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | LES LABORATOIRES SERVIER (FR) | 2025-05-30 | — | — | WO | disclosed |
| EP-4525927-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| EP-4525928-A1 | ANTIBODY DRUG CONJUGATES | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| CN-119613486-A | Antibody drug conjugates with linkers comprising hydrophilic groups | 诺华股份有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119613487-A | Antibody drug conjugates with linkers comprising hydrophilic groups | 诺华股份有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-113853219-B | Antibody drug conjugates with linkers comprising hydrophilic groups | 诺华股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| WO-2023223097-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225359-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| EP-3972650-A2 | ANTIBODY DRUG CONJUGATES HAVING LINKERS COMPRISING HYDROPHILIC GROUPS | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| CN-113853219-A | Antibody drug conjugates with linkers comprising hydrophilic groups | 诺华股份有限公司 | 2021-12-28 | — | — | CN | disclosed |
| US-20210284668-A1 | GOLD (I)-PHOSPHINE 1,2,3-TRIAZOLE DERIVATIVES WITH ANTIBIOTIC PROPERTIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-09-16 | — | — | US | disclosed |
| WO-2020236841-A2 | ANTIBODY DRUG CONJUGATES HAVING LINKERS COMPRISING HYDROPHILIC GROUPS | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| EP-3030545-B1 | AMINO ACID DERIVATIVES | MEDIMMUNE LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| WO-2019243273-A1 | GOLD (I)-PHOSPHINE 1,2,3-TRIAZOLE DERIVATIVES WITH ANTIOBIOTIC PROPERTIES | UNIVERSITÉ DE STRASBOURG (FR) | 2019-12-26 | — | — | WO | disclosed |
| US-9981908-B2 | Amino acid derivatives | MEDIMMUNE LIMITED (GB) | 2018-05-29 | — | — | US | disclosed |
| US-20160176811-A1 | Amino Acid Derivatives | ALLOZYNE, INC. | 2016-06-23 | — | — | US | disclosed |
| EP-3030545-A2 | AMINO ACID DERIVATIVES | Medimmune Limited (GB) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015019192-A2 | AMINO ACID DERIVATIVES | MEDIMMUNE LIMITED (GB) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284668-A1 | GOLD (I)-PHOSPHINE 1,2,3-TRIAZOLE DERIVATIVES WITH ANTIBIOTIC PROPERTIES | PADI3, PADI1, PADI4 | EGLN1 3245/4885TSHR 779/4885NPC1 2753/4885 |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | BID, BCL2, MCL1 | EGLN1 3340/4885TSHR 3232/4885NPC1 2842/4885 |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | FCGR2A, FCGR3B, BCL3 | EGLN1 2547/4885TSHR 1235/4885NPC1 814/4885 |
| US-20160176811-A1 | Amino Acid Derivatives | BCAT2, BCAT1, DAO | EGLN1 2399/4885TSHR 540/4885NPC1 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.